ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BGB-45035

A development code.

Its studies are mostly in Autoimmune Diseases · Arthritis, Rheumatoid, led by BeOne Medicines.

Furthest: phase 2, since Jul 28, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines20 open or runningphase 2since Jul 28, 2025Mar 26, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 26, 2024First study: phase 1 study in Autoimmune DiseasesFirst studyNCT06342713 · 203 enrolled · Australia, China, New Zealand
  2. Jul 28, 2025Phase 2 study in Arthritis, RheumatoidNCT07100938 · 49 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07100938Arthritis, Rheumatoid · China2TerminatedMay 12, 202649
NCT06342713Autoimmune Diseases · Australia, China, New Zealand1CompletedJun 2, 2026203

How it is read

Names in the registry

  • “BGB-45035”, 2 entries

Codes read as this program: BGB45035.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.